PD-L1 as a biomarker of response to immune-checkpoint inhibitors
DB Doroshow, S Bhalla, MB Beasley… - Nature reviews Clinical …, 2021 - nature.com
Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer
X Wang, J Huang, W Chen, G Li, Z Li… - Experimental & Molecular …, 2022 - nature.com
Exosomes are vesicles encompassed by a lipid bilayer that are released by various living
cells. Exosomal proteins are encapsulated within the membrane or embedded on the …
cells. Exosomal proteins are encapsulated within the membrane or embedded on the …
Exosomes and cancer-Diagnostic and prognostic biomarkers and therapeutic vehicle
X Wang, L Tian, J Lu, IOL Ng - Oncogenesis, 2022 - nature.com
Exosomes belong to a subpopulation of extracellular vesicles secreted by the dynamic
multistep endocytosis process and carry diverse functional molecular cargoes, including …
multistep endocytosis process and carry diverse functional molecular cargoes, including …
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …
Emerging role of tumor cell plasticity in modifying therapeutic response
Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …
have proposed that acquisition of resistance may result from genetic mutations. However …
Circular RNA circ-CPA4/let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC)
W Hong, M Xue, J Jiang, Y Zhang, X Gao - Journal of Experimental & …, 2020 - Springer
Background Non-small cell lung cancer (NSCLC) cells derived intracellular and extracellular
programmed cell death ligand 1 (PD-L1) promoted cancer progression and drug resistance …
programmed cell death ligand 1 (PD-L1) promoted cancer progression and drug resistance …
[HTML][HTML] The biology, function, and applications of exosomes in cancer
J Liu, L Ren, S Li, W Li, X Zheng, Y Yang, W Fu… - … Pharmaceutica Sinica B, 2021 - Elsevier
Exosomes are cell-derived nanovesicles with diameters from 30 to 150 nm, released upon
fusion of multivesicular bodies with the cell surface. They can transport nucleic acids …
fusion of multivesicular bodies with the cell surface. They can transport nucleic acids …
The cutting-edge progress of immune-checkpoint blockade in lung cancer
F Zhou, M Qiao, C Zhou - Cellular & molecular immunology, 2021 - nature.com
Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of
cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients …
cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients …